Sativex is an oromucosal spray derived from two strains of cannabis leaf and flower, cultivated for their controlled proportions of the active compounds delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).1

THC and CBD mimic actions of cannabinoid-type chemicals which occur naturally in the human body and have a role in various physiological processes.1-5

Sativex is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.1

Treatment with Sativex must be initiated and supervised by a physician with specialist expertise in treating this patient population.1

View Sativex Patient Information Leaflet 

Top